Literature DB >> 21207137

The activation of β2-adrenergic receptors in naïve rats causes a reduction of blood glutamate levels: relevance to stress and neuroprotection.

Alexander Zlotnik1, Yael Klin, Benjamin F Gruenbaum, Shaun E Gruenbaum, Sharon Ohayon, Mathew Boyko, Eyal Sheiner, Barak Aricha-Tamir, Yoram Shapira, Vivian I Teichberg.   

Abstract

This study examines the effects of the activation of β1 and β2-adrenergic receptors on glutamate homeostasis in the blood of naïve rats. Forty five male Sprague-Dawley rats were randomly assigned into one of seven treatment groups that were treated with various β-adrenergic receptor agonist and antagonist drugs. Blood glutamate levels were determined at t = 0, 30, 60, 90, and 120 min. The activation of β1 and β2-adrenergic receptors via isoproterenol hydrochloride administration produced a marked sustained decrease in blood glutamate levels by 60 min after treatment (ANOVA, t = 60, 90 min: P < 0.05, t = 120 min: P < 0.01). Pretreatment with propranolol hydrochloride (a non-selective β-adrenergic receptor blocker) or butaxamine hydrochloride (a selective β2-adrenergic receptor blocker) occluded the isoproterenol-mediated decrease in blood glutamate levels. Propranolol alone had no effect on blood glutamate levels. Selective β1-adrenergic receptor blockade with metoprolol resulted in decreased blood glutamate levels (ANOVA, t = 90 min: P < 0.05, t = 120 min: P < 0.01). Butaxamine hydrochloride alone resulted in a delayed-onset increase in glutamate levels (ANOVA, t = 120 min: P < 0.05). The results suggest that the activation of β2 receptors plays an important role in the homeostasis of glutamate in rat blood.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207137     DOI: 10.1007/s11064-010-0388-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  39 in total

1.  Beta-adrenergic receptor blockade by propranolol enhances retention in a multitrial passive-avoidance procedure.

Authors:  A M Schneider; N S Koven; K A Lombardo; D A Levin; P E Simson
Journal:  Behav Neurosci       Date:  2000-12       Impact factor: 1.912

2.  Fluorometric determination of aspartate, glutamate, and gamma-aminobutyrate in nerve tissue using enzymic methods.

Authors:  L T Graham; M H Aprison
Journal:  Anal Biochem       Date:  1966-06       Impact factor: 3.365

Review 3.  Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists.

Authors:  Keith W Muir
Journal:  Curr Opin Pharmacol       Date:  2005-12-15       Impact factor: 5.547

4.  Changes of extracellular levels of amino acids after graded compression trauma to the spinal cord: an experimental study in the rat using microdialysis.

Authors:  M Farooque; L Hillered; A Holtz; Y Olsson
Journal:  J Neurotrauma       Date:  1996-09       Impact factor: 5.269

Review 5.  Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

Authors:  Chrysanthy Ikonomidou; Lechoslaw Turski
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

Review 6.  Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies.

Authors:  V I Teichberg; K Cohen-Kashi-Malina; I Cooper; A Zlotnik
Journal:  Neuroscience       Date:  2008-03-18       Impact factor: 3.590

7.  Relationship between excitatory amino acid release and outcome after severe human head injury.

Authors:  S S Koura; E M Doppenberg; A Marmarou; S Choi; H F Young; R Bullock
Journal:  Acta Neurochir Suppl       Date:  1998

8.  Angiotensin II-induced hypothermia in rats.

Authors:  K M Wilson; M J Fregly
Journal:  J Appl Physiol (1985)       Date:  1985-02

Review 9.  Clinical experience with excitatory amino acid antagonist drugs.

Authors:  K W Muir; K R Lees
Journal:  Stroke       Date:  1995-03       Impact factor: 7.914

10.  The predictive value of catecholamines in assessing outcome in traumatic brain injury.

Authors:  P D Woolf; R W Hamill; L A Lee; C Cox; J V McDonald
Journal:  J Neurosurg       Date:  1987-06       Impact factor: 5.115

View more
  5 in total

1.  Effect of estrogens on blood glutamate levels in relation to neurological outcome after TBI in male rats.

Authors:  Alexander Zlotnik; Akiva Leibowitz; Boris Gurevich; Sharon Ohayon; Matthew Boyko; Moti Klein; Boris Knyazer; Yoram Shapira; Vivian I Teichberg
Journal:  Intensive Care Med       Date:  2011-11-29       Impact factor: 17.440

Review 2.  Extracorporeal methods of blood glutamate scavenging: a novel therapeutic modality.

Authors:  Agzam Zhumadilov; Matthew Boyko; Shaun E Gruenbaum; Evgeny Brotfain; Federico Bilotta; Alexander Zlotnik
Journal:  Expert Rev Neurother       Date:  2015-04-12       Impact factor: 4.618

Review 3.  Brain to blood glutamate scavenging as a novel therapeutic modality: a review.

Authors:  Matthew Boyko; Shaun E Gruenbaum; Benjamin F Gruenbaum; Yoram Shapira; Alexander Zlotnik
Journal:  J Neural Transm (Vienna)       Date:  2014-03-13       Impact factor: 3.575

Review 4.  Blood glutamate scavenging: insight into neuroprotection.

Authors:  Akiva Leibowitz; Matthew Boyko; Yoram Shapira; Alexander Zlotnik
Journal:  Int J Mol Sci       Date:  2012-08-13       Impact factor: 6.208

Review 5.  Glutamate as a neurotransmitter in the healthy brain.

Authors:  Y Zhou; N C Danbolt
Journal:  J Neural Transm (Vienna)       Date:  2014-03-01       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.